Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim

Executive Summary

Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership; Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.

You may also be interested in...



Emerging Markets Earnings Roundup: Pfizer And Merck (Part 5)

Pfizer and Merck have more than a deal on a diabetes candidate in common as both companies saw foreign exchange and patent expiries hit the bottom line in the first quarter and see emerging markets as key growth drivers this year.

On Amgen’s Agenda: Bring Biologics To Primary Care

The big biotech is investing heavily in two late-stage drugs – one for high cholesterol and the other for osteoporosis – that will test its ability to expand its specialty marketing savvy into primary care markets. Denosumab, launched in 2010 for osteoporosis under the brand name Prolia, was a first step, but investors see bigger opportunities ahead.

Merck’s CV Pipeline: A Shrinking But Strident Commitment

Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel